KFAS
NKTR icon

Keating Financial Advisory Services’s Nektar Therapeutics NKTR Stock Holding History

Keating Financial Advisory Services’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29K Sell
18
-51
-74% -$2.9K ﹤0.01% 2008
2025
Q4 		$2.92K Buy
+69
New +$3.86K ﹤0.01% 1466

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Keating Financial Advisory Services's NKTR Position: Q1 2026 in Review

Keating Financial Advisory Services reduced its Nektar Therapeutics (NKTR) stake by 74% in Q1 2026, selling an estimated $2.9K and leaving 18 shares worth $1.29K. The position accounts for ﹤0.01% of the portfolio, ranked #2008.

Keating Financial Advisory Services first reported a position in NKTR in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.92K in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Keating Financial Advisory Services held 18 shares of Nektar Therapeutics worth $1.29K as of Q1 2026.
  • Keating Financial Advisory Services sold 51 Nektar Therapeutics shares in Q1 2026, an estimated $2.9K.
  • Nektar Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #2008 holding.
  • Keating Financial Advisory Services first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Keating Financial Advisory Services's Nektar Therapeutics position peaked at $2.92K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.